This TRAIL/IER3 axis may therefore be a viable therapeutic target for the treatment of HCC, although further research will be necessary to validate this hypothesis and to evaluate the molecular mechanisms whereby these proteins govern HCC onset and progression. This evidence concerns the gene IER3 and hepatocellular carcinoma.